Primmune Therapeutics

About Primmune Therapeutics

Primmune is a clinical-stage biotechnology company focused on developing systemic cancer immunotherapies that activate the immune system in a precise and controlled manner. Founded by experts in oral small-molecule drug design and immune agonist pharmacology, the company aims to strengthen antitumor immunity, enhance the impact of existing treatments, and improve long-term disease control.

Products & Services

PRTX007:An orally administered, systemically active small-molecule agonist of toll-like receptor 7 (TLR7), designed to activate plasmacytoid dendritic cells (pDCs) for systemic cancer immunotherapy. It focuses on interferon-associated innate immune programs while minimizing pro-inflammatory pathways, showing promise in early clinical studies for oncology applications.

Specialties

Cancer Immunotherapy Systemic Immune Activation Toll-Like Receptor 7 (TLR7) Agonists Plasmacytoid Dendritic Cell (pDC) Activation Innate and Adaptive Immunity

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 23300000 MR: - FA: $23.3 million FAN: 23300000	D: 2026-01-26 FD: 2026-01-26	3 investors

Series B Latest

2026-01-26

$23.3M

3 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

C

Charles McDermott

President & CEO, Director

J

James Appleman

SVP, R&D and CSO

P

Paulo Rangel

Chief Business Officer and Cofounder

A

Andrew Sharabi

Chief Medical Officer

M

Marc Veale

Chief Financial Officer

S

Stephen Webber

Vice President, Medicinal Chemistry, and Cofounder

View 5 more team members with Pro

Unlock Full Team Directory

Recent News